Follistatin (FST-344)

Follistatin is a secreted, single-chain, cysteine-rich, N-glycosylated glycoprotein encoded by the human FST gene (UniProt P19883). It is studied as an extracellular antagonist of multiple TGF-β-superfamily ligands — activin A and B, myostatin (GDF-8), GDF-11, and several bone morphogenetic proteins — which it binds and holds in a non-signaling complex. Alternative splicing of the FST transcript gives rise to two precursors: the full-length FST-344 (the isoform that is the focus here, processed to the mature circulating FST-315 chain) and FST-317 (processed to the tissue-bound FST-288). The isoforms differ chiefly in an acidic C-terminal extension: FST-288 lacks it, exposing a heparin-binding sequence that anchors the protein to cell-surface heparan-sulfate proteoglycans, while the extension present in FST-315 masks that sequence, making it the predominant circulating species. A C-terminally truncated FST-303 is gonad-enriched. Because the marketed material is described as the FST-344 isoform while much of the structural and muscle literature examined FST-288 or FST-315, the summaries below attribute each line of work to the isoform actually studied and do not assume properties transfer between them.

Follistatin's domain architecture — an N-terminal domain followed by three follistatin domains (FSD1-FSD3), each composed of an EGF-like and a Kazal-like protease-inhibitor subdomain — was inferred from the human precursor sequence and gene organization characterized by Shimasaki et al. (1988), whose exon mapping supported an exon-shuffling origin. The structural basis of antagonism has been examined by X-ray crystallography. Thompson et al. (2005) solved the follistatin:activin A complex (PDB 2B0U), describing two follistatin molecules encircling the activin dimer, with the N-terminal domain adopting a fold that mimics a type I receptor motif and FSD1/FSD2 occluding the type II receptor site. Harrington et al. (2006) independently described the inhibitory arrangement using a follistatin fragment with activin A. Lerch et al. (2007) solved the FST-315:activin A complex (PDB 2P6A) and examined the biophysical coupling between heparin and activin binding across isoforms. Cash et al. (2009) solved the myostatin:follistatin-288 complex (PDB 3HH2), examining how the N-terminal domain rearranges to confer ligand specificity and how the complex surface relates to heparin association. Cash et al. (2012) followed with a domain-dissection study of the contribution of individual follistatin-type domains to activin and myostatin binding.

Follistatin was first isolated and biochemically characterized by Ueno et al. (1987), who purified it from porcine ovarian follicular fluid using heparin-Sepharose chromatography and pituitary-cell assays of follicle-stimulating-hormone (FSH) release; the native glycosylated protein was described migrating near 32-35 kDa. Nakamura et al. (1990) subsequently identified the activin-binding protein of rat ovary as follistatin, linking the FSH-regulatory context to activin sequestration. Knockout phenotyping in follistatin-deficient mice (Matzuk et al., 1995) examined the developmental consequences of loss of the gene. Together these reports established follistatin as a regulator within the activin/inhibin axis and provided the reproductive-endocrinology framing for later work in other tissues.

Because myostatin (GDF-8) is among the ligands follistatin binds, a substantial preclinical literature has examined follistatin within skeletal-muscle and myostatin-pathway model systems, largely through transgenic overexpression or AAV-mediated gene delivery rather than administration of exogenous protein. Transgenic and genetic-epistasis studies (Lee & McPherron, 2001; Lee, 2007) examined follistatin in combination with myostatin-pathway perturbations in mouse skeletal-muscle model systems. Gene-delivery work examined AAV-delivered follistatin (FS344) in normal and dystrophic (mdx) mice (Haidet et al., 2008) and in nonhuman primates (Kota et al., 2009), where skeletal-muscle and organ-safety measures were assessed. Later studies examined engineered follistatin-based ligand traps — follistatin-Fc fusion constructs — in wild-type and mdx mouse skeletal-muscle model systems (Pearsall et al., 2019; Shen et al., 2019). Across these reports the molecule studied is generally a follistatin transgene or an engineered construct, and findings from constitutive overexpression or gene delivery are not assumed to transfer to acute protein administration.

Follistatin belongs to a small family of follistatin-domain antagonists. FSTL3 (also called FLRG) is a related secreted protein that, like follistatin, binds activins and myostatin but lacks the heparin-binding behavior of FST-288; it was identified and characterized as a TGF-β-family binding protein by Tsuchida et al. (2000). Beyond muscle and reproduction, the activin/follistatin axis has been examined in inflammation and endotoxin-challenge model systems and in expression-profiling studies across carcinoma model-system contexts, where activin, inhibin, and follistatin levels are surveyed as part of TGF-β-superfamily signaling. The connective-tissue and fibrosis-marker context (assessment of markers such as TGF-β, collagen, and fibronectin within these model systems) has also been examined within the muscle gene-delivery studies described above. These strands position follistatin as a node in TGF-β-superfamily regulation studied across several model systems.

Follistatin (FST-344) has been examined in registered gene-transfer studies documented on ClinicalTrials.gov. An AAV1-delivered follistatin (FS344) program was registered in a Becker muscular dystrophy and inclusion-body-myositis research context (NCT01519349), with associated open-label reports by Mendell et al. (2015) and Mendell et al. (2017); a published commentary by Greenberg (2017) discussed the inclusion-body-myositis report. A separate registered study examined AAV1-delivered follistatin (FS344) in a Duchenne muscular dystrophy research context (NCT02354781). These descriptions note only the design and research context of the studies; the body of follistatin protein and gene-delivery work overall remains predominantly preclinical, built on in vitro biochemistry, structural biology, and rodent and nonhuman-primate model systems.